Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 4,801 trials in your specialties ()
View trials across your selected specialties

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Glioblastoma
View Full Trial
INTERVENTION

Drug: hrBMP4

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Brief Summary

The purpose of the study is to evaluate the feasibility and safety of intra-tumor and interstitial therapy with hBMP4 in increasing doses in patients with progressive and/or multiple recurrent Glioblastoma multiforme (GBM).

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Heart Failure
View Full Trial
INTERVENTION

Drug: Empagliflozin 10Mg Tab, Drug: Placebo Oral Tablet

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Southern California, Los Angeles, California, United States

Brief Summary

The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device implanted for non-study related clinical reasons.

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Crohn's Disease (CD)
View Full Trial
INTERVENTION

Drug: ABT-494

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Moore UC San Diego Cancer Center /ID# 150041, La Jolla, California, United States

Brief Summary

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Alcohol Use Disorder
View Full Trial
INTERVENTION

Behavioral: Bias retraining, Behavioral: Sham retraining

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Michigan Addiction Research Center, Ann Arbor, Michigan, United States

Brief Summary

This study investigates the effect of a computerized approach/avoidance retraining (aka cognitive bias modification) over and above treatment as usual for patients in treatment for substance use disorders. The computerized training entails viewing pictures of drug and non-drug related stimuli, and then using the computer to make the drug pictures smaller and the non-drug pictures larger. Participants will also take part in an EEG/event-related brain potential assessment at the beginning and end of treatment to identify brain measures that are associated with treatment response.

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophili...
View Full Trial
INTERVENTION

Drug: AK002

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Phoenician Centers for Research and Innovation, Phoenix, Arizona, United States

Brief Summary

This is a Phase 2, open-label, extension study to assess the safety and tolerability of AK002, given monthly for up to 26 doses.

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Atopic Dermatitis
View Full Trial
INTERVENTION

Drug: Upadacitinib

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

TU Uniklinik Munchen /ID# 214221, Munich, Germany

Brief Summary

This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

  • Status
    Active, not recruiting
  • Phase
    Phase 2 Phase 3
  • Condition
    Gliosarcoma, Glioblastoma
View Full Trial
INTERVENTION

Drug: Temozolomide, Drug: ABT-414, Radiation: Radiation, Drug: Placebo for ABT-414

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

St. Josephs Hosp and Med Ctr /ID# 144149, Phoenix, Arizona, United States

Brief Summary

This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification. In addition, there is a Phase 1, open-label, multicenter sub-study to assess the pharmacokinetics, safety and tolerability of ABT-414 in participants with newly diagnosed EGFR-amplified GBM who have mild or moderate hepatic impairment.

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma...
View Full Trial
INTERVENTION

Biological: Dendritic Cell Vaccine, Biological: Tumor Lysate, Drug: Imiquimod, Procedure: Leukapheresis

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Miami, Miami, Florida, United States

Brief Summary

The purpose of this research study is to evaluate an investigational vaccine using patent-derived dendritic cells (DC) to treat malignant glioma or glioblastoma.

Study Evaluating Subjects With Distal Renal Tubular Acidosis

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Distal Renal Tubular Acidosis
View Full Trial
INTERVENTION

Drug: ADV7103, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California, San Francisco, California, United States

Brief Summary

This is a phase 3, prospective, multicenter, randomized, double-blinded, placebo-controlled, study product withdrawal study comparing the efficacy of ADV7103 versus placebo in preventing the development of metabolic acidosis defined by serum bicarbonate level in pediatric (6 months to < 18 years of age) and adult (18 to 65 years of age) subjects with primary dRTA.

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Glioblastoma
View Full Trial
INTERVENTION

Biological: Ad-RTS-hIL-12, Drug: Veledimex, Drug: Cemiplimab-Rwlc

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Cedars Sinai, Los Angeles, California, United States

Brief Summary

This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Cemiplimab-rwlc (Libtayo) is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Libtayo (cemiplimab-rwlc) is currently FDA approved in the United States for metastatic cutaneous cell carcinoma (CSCC), but is not approved in glioblastoma. Cemiplimab-rwlc may help your immune system detect and attack cancer cells. Ad-RTS-hIL-12 and veledimex will be given in combination with cemiplimab-rwlc to enhance the IL-12 mediated effect observed to date. The main purpose of this study is to evaluate the safety and efficacy of a single tumoral injection of Ad-RTS-hIL-12 given with oral veledimex in combination with cemiplimab-rwlc.